Jove
Visualize
Contact Us
JoVE
x logofacebook logolinkedin logoyoutube logo
ABOUT JoVE
OverviewLeadershipBlogJoVE Help Center
AUTHORS
Publishing ProcessEditorial BoardScope & PoliciesPeer ReviewFAQSubmit
LIBRARIANS
TestimonialsSubscriptionsAccessResourcesLibrary Advisory BoardFAQ
RESEARCH
JoVE JournalMethods CollectionsJoVE Encyclopedia of ExperimentsArchive
EDUCATION
JoVE CoreJoVE BusinessJoVE Science EducationJoVE Lab ManualFaculty Resource CenterFaculty Site
Terms & Conditions of Use
Privacy Policy
Policies

Filters

Michael Ong

Showing results (81-90 of 117) with videos related to

Pageof 12
Sort By:
Cancers|January 25, 2025
Diagnosis and Management of Skin Toxicities in Systemic Treatment of Genitourinary CancersDeepro Chowdhury, Laura Chin, Roupen Odabashian, et al.
BMJ (Clinical Research Ed.)|December 21, 2023
Common Healthcare Related Instruments Subjected To Magnetic Attraction Study (CHRISTMAS): prospective in situ experimental studyShao J Ong, Koon Liang Chia, Teik Choon See, et al.
Annals of Internal Medicine|November 18, 2014
12-month outcomes of community engagement versus technical assistance to implement depression collaborative care: a partnered, cluster, randomized, comparative effectiveness trialBowen Chung, Michael Ong, Susan L Ettner, et al.
Clinical Cancer Research : an Official Journal of the American Association for Cancer Research|March 26, 2015
First-in-Human Pharmacokinetic and Pharmacodynamic Study of the Dual m-TORC 1/2 Inhibitor AZD2014Bristi Basu, Emma Dean, Martina Puglisi, et al.
Journal of Bone Oncology|September 27, 2021
Two-year results of a randomised trial comparing 4- versus 12-weekly bone-targeted agent use in patients with bone metastases from breast or castration-resistant prostate cancerMark Clemons, Michelle Liu, Carol Stober, et al.
European Journal of Cancer (Oxford, England : 1990)|September 7, 2024
Effect of concomitant medications on treatment response and survival in non-metastatic castrate resistant prostate cancer: Exploratory analysis of the SPARTAN trialSoumyajit Roy, Fred Saad, Yilun Sun, et al.
Clinical Nutrition (Edinburgh, Scotland)|February 26, 2026
Dietary potassium and fiber intake, survival, and health-related quality of life, in a prospective multi-center hemodialysis cohortYoko Narasaki, Zhaoping Li, Michael Ong, et al.
The Journal of Urology|April 9, 2021
Safety and Efficacy of Atezolizumab in Understudied Populations with Pretreated Urinary Tract Carcinoma: Subgroup Analyses of the SAUL Study in Real-World PracticeAxel S Merseburger, Daniel Castellano, Thomas Powles, et al.
Innovations in Clinical Neuroscience|August 18, 2020
Depression in Heart Failure: A Systematic ReviewWaguih William Ishak, Gabriel Edwards, Nathalie Herrera, et al.
European Journal of Cancer (Oxford, England : 1990)|October 7, 2020
A randomised trial of 4- versus 12-weekly administration of bone-targeted agents in patients with bone metastases from breast or castration-resistant prostate cancerMark Clemons, Michael Ong, Carol Stober, et al.
Pageof 12

Showing results (81-90 of 117) with videos related to

Sort By:
Pageof 12
Cancers|January 25, 2025
Diagnosis and Management of Skin Toxicities in Systemic Treatment of Genitourinary CancersDeepro Chowdhury, Laura Chin, Roupen Odabashian, et al.
BMJ (Clinical Research Ed.)|December 21, 2023
Common Healthcare Related Instruments Subjected To Magnetic Attraction Study (CHRISTMAS): prospective in situ experimental studyShao J Ong, Koon Liang Chia, Teik Choon See, et al.
Annals of Internal Medicine|November 18, 2014
12-month outcomes of community engagement versus technical assistance to implement depression collaborative care: a partnered, cluster, randomized, comparative effectiveness trialBowen Chung, Michael Ong, Susan L Ettner, et al.
Clinical Cancer Research : an Official Journal of the American Association for Cancer Research|March 26, 2015
First-in-Human Pharmacokinetic and Pharmacodynamic Study of the Dual m-TORC 1/2 Inhibitor AZD2014Bristi Basu, Emma Dean, Martina Puglisi, et al.
Journal of Bone Oncology|September 27, 2021
Two-year results of a randomised trial comparing 4- versus 12-weekly bone-targeted agent use in patients with bone metastases from breast or castration-resistant prostate cancerMark Clemons, Michelle Liu, Carol Stober, et al.
European Journal of Cancer (Oxford, England : 1990)|September 7, 2024
Effect of concomitant medications on treatment response and survival in non-metastatic castrate resistant prostate cancer: Exploratory analysis of the SPARTAN trialSoumyajit Roy, Fred Saad, Yilun Sun, et al.
Clinical Nutrition (Edinburgh, Scotland)|February 26, 2026
Dietary potassium and fiber intake, survival, and health-related quality of life, in a prospective multi-center hemodialysis cohortYoko Narasaki, Zhaoping Li, Michael Ong, et al.
The Journal of Urology|April 9, 2021
Safety and Efficacy of Atezolizumab in Understudied Populations with Pretreated Urinary Tract Carcinoma: Subgroup Analyses of the SAUL Study in Real-World PracticeAxel S Merseburger, Daniel Castellano, Thomas Powles, et al.
Innovations in Clinical Neuroscience|August 18, 2020
Depression in Heart Failure: A Systematic ReviewWaguih William Ishak, Gabriel Edwards, Nathalie Herrera, et al.
European Journal of Cancer (Oxford, England : 1990)|October 7, 2020
A randomised trial of 4- versus 12-weekly administration of bone-targeted agents in patients with bone metastases from breast or castration-resistant prostate cancerMark Clemons, Michael Ong, Carol Stober, et al.
Pageof 12